RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients living with inflammatory and immunological diseases. The company's lead drug candidate, RPT904, is a half-life extended monoclonal antibody designed to bind free human immunoglobin E (IgE), a key driver of several allergic diseases. In December 2024, RAPT Therapeutics, Inc. entered into an exclusive license agreement with Shanghai Jemincare Pharmaceutical Co., Ltd, a subsidiary of Jiangxi Jemincare Group Co., Ltd., granting RAPT Therapeutics, Inc. exclusive rights to develop and commercialize RPT904 worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is being developed as a potential therapeutic option for conditions like food allergy and chronic spontaneous urticaria (CSU). In a Phase 1 clinical trial, RPT904 demonstrated a median half-life more than two times that of omalizumab at the same dose, along with deeper and more sustained reduction of free IgE and higher total IgE accumulation compared to omalizumab at the same dose. The company also has an oncology drug candidate, tivumecirnon, an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist. Tivumecirnon is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors. Data from a Phase 2 trial in patients with advanced checkpoint-naïve non-small cell lung cancer (NSCLC) treated with tivumecirnon in combination with pembrolizumab showed a greater confirmed objective response rate and progression-free survival than historically demonstrated by pembrolizumab monotherapy. RAPT Therapeutics, Inc. holds worldwide rights to tivumecirnon, except for an exclusive license granted to Hanmi Pharmaceutical Ltd. in Korea, mainland China, Hong Kong, Macau, and Taiwan. The company is seeking a partner to further develop tivumecirnon outside of this Hanmi Territory.